Author

Emma V. Casella

University of Brescia

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alessandro FanzaniiD· 1 shared Daniel C. AnderssoniD· 1 shared Silvia CodenottiiD· 1 shared Stefano GastaldelloiD· 1 shared Volker Martin LauschkeiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

5 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alessandro FanzaniORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Synthetic inhibition of the SUMO pathway by targeting the SAE1 component via TAK-981 compound impairs tumor growth and chemosensitizers embryonal and alveolar rhabdomyosarcoma cell lines.

Silvia Codenotti, Volker Martin Lauschke, Emma V. Casella, Daniel C. Andersson, Alessandro Fanzani, Stefano Gastaldello

This study shows that TAK-981, a SUMO inhibitor targeting SAE1, reduces RMS cell growth and enhances chemotherapy effectiveness without increasing radiosensitivity.

bioRxiv · Jan 15, 2025 · PreprintCancer Biology